M
Maria V. Irazabal
Researcher at Mayo Clinic
Publications - 62
Citations - 2570
Maria V. Irazabal is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Autosomal dominant polycystic kidney disease & Polycystic kidney disease. The author has an hindex of 23, co-authored 58 publications receiving 1883 citations.
Papers
More filters
Journal ArticleDOI
Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials
Maria V. Irazabal,Laureano J. Rangel,Eric J. Bergstralh,Sara L. Osborn,Amber J. Harmon,Jamie L. Sundsbak,Kyongtae T. Bae,Arlene B. Chapman,Jared J. Grantham,Michal Mrug,Marie C. Hogan,Ziad M. El-Zoghby,Peter C. Harris,Bradley J. Erickson,Bernard F. King,Vicente E. Torres +15 more
TL;DR: A longitudinal mixed regression model to predict eGFR decline showed that log2HtTKV and age significantly interacted with time in typical patients, but not in atypical patients.
Journal ArticleDOI
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fernando C. Fervenza,Roshini S. Abraham,Stephen B. Erickson,Maria V. Irazabal,Alfonso Eirin,Ulrich Specks,Patrick H. Nachman,Eric J. Bergstralh,Nelson Leung,Fernando G. Cosio,Marie C. Hogan,John J. Dillon,La Tonya J. Hickson,Xujian Li,Daniel C. Cattran +14 more
TL;DR: Four doses of RTX resulted in more effective B cell depletion, but proteinuria reduction was similar to RTX at 1 g every 2 weeks, which could potentially result in undertreatment.
Journal ArticleDOI
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease
Christina M. Heyer,Jamie L. Sundsbak,Kaleab Z. Abebe,Arlene B. Chapman,Vicente E. Torres,Jared J. Grantham,Kyongtae T. Bae,Robert W. Schrier,Ronald D. Perrone,William E. Braun,Theodore I. Steinman,Michal Mrug,Alan S.L. Yu,Godela Brosnahan,Katharina Hopp,Maria V. Irazabal,William M. Bennett,Michael F. Flessner,Charity G. Moore,Douglas Landsittel,Peter C. Harris +20 more
TL;DR: Overall, the contribution of genic and PKD1 allelic effects and sex to the ADPKD phenotype is quantified and it is shown that other factors shared by families influence htTKV, with these additional genetic/environmental factors significantly affecting the AD PKD phenotype.
Journal ArticleDOI
Reactive Oxygen Species and Redox Signaling in Chronic Kidney Disease.
TL;DR: The main sources of ROS and antioxidant systems in the kidney, and redox signaling pathways leading to inflammation and fibrosis, which result in abnormal kidney function and CKD progression are discussed.
Journal ArticleDOI
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years
Marie C. Hogan,Tetyana V. Masyuk,Linda J. Page,David R. Holmes,Xujian Li,Eric J. Bergstralh,Maria V. Irazabal,Bohyun Kim,Bernard F. King,James F. Glockner,Nicholas F. LaRusso,Vicente E. Torres +11 more
TL;DR: Over 2 years, OctLAR significantly reduced the rate of increase in TLV and possibly the rate for increase in TKV and overall physical and mental improvements were not significant during Year 2 compared to Year 1.